Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user noticed hair thinning and started using Viviscal, Minoxidil, and keto shampoo, along with taking vitamin D, Omega 3, and magnesium. They feel their hair has improved but question if Viviscal contributes to hair growth and thickness.

A user is attempting to reformulate a topical gel using PP-405 for hair loss, aiming to enhance its effectiveness with additional compounds. They discuss the potential of PP-405 compared to other treatments like Minoxidil and GT20029, and emphasize the importance of proper formulation for efficacy.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

PP405 and JXL-069 are the same compound, but users experienced no results due to flawed application methods. The topical gel formulation of PP405 is designed to target hair follicle stem cells effectively, unlike liquid solutions that fail to penetrate deeply.

The conversation discusses the potential benefits and risks of participating in the PP405 hair loss trials, emphasizing that those using Minoxidil or finasteride are less likely to be accepted. Participants are interested in the trial as it offers hope for effective treatment without the side effects associated with current medications.

The user started with oral minoxidil and switched to 2.5mg dutasteride, experiencing significant hair growth without side effects. They believe dutasteride has fewer side effects than finasteride due to its action on both type 1 and 2 5-alpha reductase enzymes.

PP405 shows promise in reactivating dormant hair follicles, with early trials indicating some success, but it is not yet a proven treatment for hair loss. Users are advised to be cautious with unverified versions, and further research is needed to confirm its effectiveness compared to treatments like minoxidil and finasteride.

VDPHL01, an extended-release oral minoxidil tablet, showed promising results in improving hair coverage for 79 to 86% of men in a trial, with fewer side effects compared to standard doses. Many users prefer oral minoxidil over topical due to ease of use and fewer side effects, especially for those with pets.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

The user noticed thicker hair and reduced dandruff after using Nizoral 2% (ketoconazole) every few days, alongside topical minoxidil 5% for over a year. They plan to reduce Nizoral use to once a week to avoid scalp irritation.

Treatments for hair loss, such as topical minoxidil, platelet-rich plasma therapy with or without minoxidil, ketoconazole, non-abative radio frequency, natural products, finasteride and cortexolone 17 alpha propionate. The post evaluates the efficacy and safety of these treatments in various studies.

PP405 is in a phase 3 trial for hair loss treatment, with the study expected to run until June 2028. Minoxidil and finasteride remain key treatments, with hopes for PP405 to offer a new mechanism of action.

Switching from powdered dutasteride to softgel significantly reduced DHT levels, suggesting softgels are more effective due to better bioavailability. Users discuss the ineffectiveness of compounded forms and emphasize the importance of proper formulation for absorption.

PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.

The conversation humorously discusses hair loss treatments, focusing on finasteride, dutasteride, minoxidil, and microneedling. Users share experiences and opinions on the effectiveness and side effects of these treatments.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

The user increased their dutasteride dose from 0.5mg to 3mg daily to address hair thinning, noticing a change in shedding patterns and possibly thicker hair. Other users discuss the effectiveness of different dutasteride doses on DHT levels and suggest staying consistent with the treatment.

PP405, a potential treatment for male pattern baldness, shows promise with some participants experiencing hair regrowth in early trials. However, it is not yet considered a cure and may be used alongside existing treatments like minoxidil and finasteride.

Using a derma stamp instead of a derma roller for hair growth is more effective and less damaging. The user experienced hair improvement with oral finasteride, topical minoxidil, and a derma stamp.

Minoxidil and finasteride are effective for hair loss, but natural oils like pumpkin seed oil and saw palmetto are not proven to be effective. Topical finasteride may be an option for those who cannot tolerate oral finasteride.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

The conversation discusses various hair loss treatments, including Minoxidil, Dutasteride, Finasteride, and Tretinoin, with users sharing personal experiences and side effects. It reflects on generational attitudes towards hair loss and the emotional impact of hair loss remedies.

Topical finasteride may reduce more scalp DHT but is seen as inconsistent and messy compared to oral finasteride. Users report mixed results with both forms, with some preferring oral for its convenience and consistent dosing, while others find topical effective but harder to apply.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

The user tried Finasteride, Dutasteride, Minoxidil, RU58841, dermarolling, and oral castor oil for hair loss. They found RU58841 and Minoxidil most effective with no side effects, while Finasteride and Dutasteride caused sexual side effects.

A 25-year-old male is experiencing positive temple regrowth after using 1 mg oral finasteride daily and a custom topical solution from Musely containing minoxidil, dutasteride, tretinoin, ketoconazole, and hydrocortisone. He is considering adding dermarolling to enhance results, while others share their experiences and suggestions for hair regrowth treatments.

Dutasteride and finasteride may temporarily affect semen quality but are unlikely to cause permanent infertility. The Kim et al. study is criticized for poor methodology, and many prefer hair retention over potential fertility concerns, using treatments like dutasteride, finasteride, and minoxidil.